Based on a synthesis of best available evidence, the American Gastroenterological Association (AGA) has released clinical recommendations on fecal microbiota-based therapies (FMT) in adults with gastrointestinal […]

Approximately 1 in 12 adults worldwide has fecal incontinence (FI), according to a recent meta-analysis. FI is more common among individuals 60 years and older, yet […]

The US Food and Drug Administration (FDA) has approved resmetirom (Rezdiffra, Madrigal Pharmaceuticals), the first drug to treat patients with metabolic dysfunction–associated steatohepatitis (MASH) and moderate […]

On a November morning in 2022, James Messenger opened wide and swallowed a capsule like no other. Messenger was no stranger to taking pills. He’d first […]

TOPLINE: The vast majority of insurance companies require patients with Crohn’s disease and ulcerative colitis to fail conventional treatment with steroids and immunomodulators before starting biologic […]

Managing the intense demands of their profession with the need for sufficient time off for family, vacation, and other personal activities is a constant struggle for […]

(Reuters) -Ionis Pharmaceuticals said on Wednesday its experimental drug to treat a type of fatty liver disease met the main goal of reducing inflammation of the […]

To what extent can our intestinal microbiota predict the risk of developing diseases? In the case of multifactorial diseases, bacterial taxa alone do not provide much […]

TOPLINE: Higher dietary niacin intake is associated with a lower risk for all-cause mortality among people with metabolic dysfunction-associated steatotic liver disease (MASLD), but there is […]